title: Lithium for post-electroconvulsive therapy depressive relapse prevention: a consideration of the evidence.
abstract: Lithium has been used for several decades as a prophylactic against depressive relapse after successful index electroconvulsive therapy (ECT). The literature on this topic is reviewed, and it is concluded that, in the main, there is strong evidence that lithium can help prevent relapses in the first 6 months after index ECT. However, there are several unanswered questions about its use post-ECT, including optimal target blood level, duration of use, and concomitant antidepressant choice. In this report, the author provides a review of the evidence for using lithium in this setting, outlines the pertinent unanswered questions, and proposes future research directions and guidelines for current clinical care.
authors.affiliation: From the Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN.
authors.forename: Keith G
authors.initials: KG
authors.lastname: Rasmussen
mesh_terms: D000928:Antidepressive Agents / Q000627:therapeutic use; D018692:Antimanic Agents / Q000097:blood / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003866:Depressive Disorder / Q000188:drug therapy* / Q000628:therapy*; D004565:Electroconvulsive Therapy / Q000379:methods*; D006801:Humans; D008094:Lithium / Q000097:blood / Q000627:therapeutic use*; D012008:Recurrence
chemical_list: D000928:Antidepressive Agents; D018692:Antimanic Agents; D008094:Lithium